c-MYC and h-TERT co-expression in colon adenocarcinoma: A tissue microarray digitized image analysis

Journal of B.U.ON.

Volumn 18, Issue 1, 2013, Pages 124-130

  Georgakopoulos, G ^a   Tsiambas, Evangelos ^b   Korkolopoulou, P ^b   Kavantzas, N ^b   Karameris, A ^c   Ragkos, V ^d   Rigopoulos, D N ^e   Vilaras, G ^b   Patsouris, E ^b,b   Athanasiou, A E ^f   Tatsiou, D ^a  

^a General Hospital of Thiva   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c 417 V A Hospital of Athens   (Greece)

^d UNIVERSITY OF IOANNINA   (Greece)

^e 401 GENERAL MILITARY HOSPITAL OF ATHENS   (Greece)

^f METAXA CANCER HOSPITAL   (Greece)

Author keywords

c MYC; Colon carcinoma; Genes; Image analysis; Immunohistochemistry; Telomerase

Indexed keywords

MYC PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; COLON ADENOCARCINOMA; DIGITAL IMAGING; DISEASE ASSOCIATION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

EID: 84879005156     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Wiedmann MW, Casa K. Molecular targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 2005; 5: 171-193. (Pubitemid 40694859)
2. Lagerstedt KK, Staaf J, Jonsson G. Tumor genome wide DNA alterations assessed by array CGH in patients with poor and excellent survival following operation for colorectal cancer. Cancer Inf 2007; 3: 351-365.
3. Molina J, Adjei A. The Ras/Raf/MAPK Pathway. J Thorac Oncol 2006; 1: 7-9. (Pubitemid 47164015)
4. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Disc 2004; 3: 391-400. (Pubitemid 38618122)
5. Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo V. Epidermal growth factor receptor, c-met, b-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 2004; 10: 3069-3075. (Pubitemid 38619685)
6. Croce CM, Thierfelder W, Erikson J et al. Transcriptional activation of an un rearranged and untranslocated c-myc oncogene by translocation of a C lambda locus in Burkitt. Proc Natl Acad Sci USA 1983; 80: 6922-6926. (Pubitemid 14234404)
7. Leone G, Sears R, Huang E et al. Myc requires distinct E2F activities to induce S phase and apoptosis. Molec Cell 2001; 8: 105-113. (Pubitemid 32772909)
8. Wu KJ, Grandori C, Amacker M et al. Direct activation of TERT transcription by c-MYC. Nat Genet 1999; 21: 220-224. (Pubitemid 29070372)
9. Kolquist KA, Ellisen LW, Counter CM et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet 1998; 19: 182-186. (Pubitemid 28248803)
10. Padilla-Nash HM, Hathcock K, McNeil NE et al. Spontaneous transformation of murine epithelial cells requires the early acquisition of specific chromosomal aneuploidies and genomic imbalances. Genes Chromosomes Cancer 2012; 51:353-374.
11. Robert F, Mills JR, Agenor A et al. Targeting protein synthesis in a Myc/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival. Cancer Res 2012;1;72:747-756.
12. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. Cell 1985; 43: 405-413. (Pubitemid 16213265)
13. Dhaene K, Van Marck E, Parwaresch R. Telomeres, telomerase and cancer: an up date. Virchows Arch 2000; 437: 1-16.
14. Hsu CP, Miaw J, Hsia JY, Shai SE, Chen CY. Concordant expression of the telomerase-associated genes in non small cell lung cancer. Eur J Surg Oncol 2003; 29: 594-599. (Pubitemid 37121760)
15. Zulhabri O, Rahman J, Ismail S, Isa MR, Wan Zurinah WN. Predominance of G to A codon 12 mutation K-ras gene in Dukes' B colorectal cancer. Singapore Med J 2012; 53:26-31.
16. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonist in the biology and treatment of cancer. J Clin Oncol 2003; 21: 2787-2799. (Pubitemid 46606324)
17. Adb El, All HS, Mishriky AM, Mohamed FA. Epidermal growth factor receptor in colorectal carcinoma: correlation with clinico-pathological prognostic factors. Colorectal Dis 2008; 10: 170-178.
18. Moroni M, Veronese S, Benvenuti S et al. Gene copy number for epidermal growth factor receptor EGFR and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6: 279-286. (Pubitemid 40590264)
19. Liu Z, Brooks RS, Ciappio ED et al. Diet-induced obesity elevates colonic TNF-α in mice and is accompanied by an activation of Wnt signaling: a mechanism for obesity-associated colorectal cancer. J Nutr Biochem 2011; 23: 1207-1213.
20. Kang YJ, Park HJ, Chung HJ et al. Wnt/β-catenin Signaling Mediates the Antitumor Activity of Magnolol in Colorectal Cancer Cells. Mol Pharmacol 2012; 82: 168-177.
21. Kumar KN, Raja SB, Vidhya N, Devaraj SN. Ellagic acid modulates antioxidant status, ornithine decarboxylase expression, and aberrant crypt foci progression in 1,2-dimethylhydrazine-instigated colon preneoplastic lesions in rats. J Agric Food Chem 2012; 60:3665-3672.
22. Peiró-Jordán R, Krishna-Subramanian S, Hanski ML et al. The chemopreventive agent ursodeoxycholic acid inhibits proliferation of colon carcinoma cells by suppressing c-Myc expression. Eur J Cancer Prev 2012; 21: 413-422.
23. Pagán B, Isidro AA, Cruz ML et al. Erlotinib inhibits progression to dysplasia in a colitis-associated colon cancer model. World J Gastroenterol 2011; 17:4858-4866.
24. Wright JB, Brown SJ, Cole MD. Upregulation of c-MYC in cis through a large chromatin loop linked to a cancer risk-associated single-nucleotide polymorphism in colorectal cancer cells. Mol Cell Biol 2010; 30:1411-1420.
25. Arango D, Mariadason JM, Wilson AJ et al. c-Myc over expression sensitises colon cancer cells to camptothecin-induced apoptosis. Br J Cancer 2003; 89:1757-1765. (Pubitemid 37464151)
26. Bottone MG, Soldani C, Tognon G et al. Multiple effects of paditaxel are modulated by a high c-myc amplification level. Exp Cell Res 2003; 290:49-59. (Pubitemid 37153250)
27. Li N, Wang J, Shen S, Bu X, Tian X, Huang P. Expression of p53, Ki-67 and c-Myc proteins is predictive of the surgical molecular margin in colorectal carcinoma. Pathol Oncol Res 2011; 17:479-487.
28. Tabach Y, Kogan-Sakin I, Buganim Y et al. Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLoS One 2011; 6:e14632.
29. Wang L, Soria JC, Kemp BL, Liu DD, Mao L, Khuri FR. hTERT expression is a prognostic factor of survival in patients with stage I non-small cell lung cancer. Clin Cancer Res 2002; 8: 2883-2889. (Pubitemid 35025735)
30. Tsiambas E, Stamatelopoulos A, Baltayiannis N et al. Evaluation of combined telomerase and c-myc expression in non-small cell lung carcinomas using tissue microarrays and computerized image analysis. J BUON 2005; 10:533-539. (Pubitemid 43285560)
31. Zou J, Yu XF, Bao ZJ, Dong J. Proteome of human colon cancer stem cells: a comparative analysis. World J Gastroenterol 2011; 17:1276-1285.
32. Chen CH, Chen RJ. Prevalence of telomerase activity in human cancer. J Formos Med Assoc 2011;110:275-289.
33. Pellatt AJ, Wolff RK, Herrick J, Lundgreen A, Slattery ML. TERT's role in colorectal carcinogenesis. Mol Carcinog 2012 (in press).
34. Hofer P, Baierl A, Feik E, Führlinger G et al. MNS16A tandem repeats minisatellite of human telomerase gene: a risk factor for colorectal cancer. Carcinogenesis 2011; 32:866-871.
35. Flavin P, Redmond A, McBryan J et al. RuvBl2 cooperates with Ets2 to transcriptionally regulate hTERT in colon cancer. FEBS Lett 2011; 585:2537-2544.
36. Cosan DT, Soyocak A, Basaran A, Degirmenci I, Gunes HV, Sahin FM. Effects of various agents on DNA fragmentation and telomerase enzyme activities in adenocarcinoma cell lines. Mol Biol Rep 2011; 38:2463-2469.
37. Lu Y, Gu J, Jin D, Gao Y, Yuan M. Inhibition of telomerase activity by HDV ribozyme in cancers. J Exp Clin Cancer Res 2011; 30: 2-7.